Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China
Background: The drug therapy of venous thromboembolism (VTE) presents a significant economic burden to the health-care system in low- and middle-income countries. To understand which anticoagulation therapy is most cost-effective for clinical decision-making , the cost-effectiveness of apixaban (API...
Saved in:
Main Authors: | Ke-Xin Sun (Author), Bin Cui (Author), Shan-Shan Cao (Author), Qi-Xiang Huang (Author), Ru-Yi Xia (Author), Wen-Jun Wang (Author), Jing-Wen Wang (Author), Feng Yu (Author), Yi Ding (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of novel oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolism
by: Maodi Xu, et al.
Published: (2018) -
Recent advances in mechanism and anticoagulant therapy of venous thromboembolism in patients with non-dialysis chronic kidney disease
by: Jia-xin Wang, et al.
Published: (2024) -
Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different?
by: Łukasz Wołowiec, et al.
Published: (2017) -
Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different?
by: Łukasz Wołowiec, et al.
Published: (2017) -
New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events
by: Mekaj YH, et al.
Published: (2015)